IN2015DN00528A - - Google Patents
Info
- Publication number
- IN2015DN00528A IN2015DN00528A IN528DEN2015A IN2015DN00528A IN 2015DN00528 A IN2015DN00528 A IN 2015DN00528A IN 528DEN2015 A IN528DEN2015 A IN 528DEN2015A IN 2015DN00528 A IN2015DN00528 A IN 2015DN00528A
- Authority
- IN
- India
- Prior art keywords
- combination
- proliferative disease
- subject
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000002062 proliferating effect Effects 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 abstract 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683790P | 2012-08-16 | 2012-08-16 | |
| PCT/US2013/054848 WO2014028566A1 (en) | 2012-08-16 | 2013-08-14 | Combination of pi3k inhibitor and c-met inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00528A true IN2015DN00528A (esLanguage) | 2015-06-26 |
Family
ID=49004065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN528DEN2015 IN2015DN00528A (esLanguage) | 2012-08-16 | 2013-08-14 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20150216870A1 (esLanguage) |
| EP (1) | EP2885003B1 (esLanguage) |
| JP (3) | JP2015529194A (esLanguage) |
| KR (2) | KR102245985B1 (esLanguage) |
| CN (1) | CN105050623B (esLanguage) |
| AU (4) | AU2013302702A1 (esLanguage) |
| BR (1) | BR112015002528A2 (esLanguage) |
| CA (1) | CA2879704A1 (esLanguage) |
| ES (1) | ES2901712T3 (esLanguage) |
| HK (1) | HK1211476A1 (esLanguage) |
| IN (1) | IN2015DN00528A (esLanguage) |
| MX (1) | MX369518B (esLanguage) |
| RU (1) | RU2705095C2 (esLanguage) |
| WO (1) | WO2014028566A1 (esLanguage) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| CA2914310A1 (en) * | 2013-06-18 | 2014-12-24 | Novartis Ag | Pharmaceutical combinations |
| CA2917858A1 (en) | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| CA2954840A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide |
| ES2784900T3 (es) | 2014-12-12 | 2020-10-01 | Massachusetts Gen Hospital | Tratamiento de metástasis cerebrales del cáncer de mama |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| KR20220119427A (ko) * | 2019-12-20 | 2022-08-29 | 리커리엄 아이피 홀딩스, 엘엘씨 | 조합 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| SI3034075T1 (sl) * | 2006-11-22 | 2018-12-31 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaze |
| CN101616672A (zh) * | 2007-02-20 | 2009-12-30 | 诺瓦提斯公司 | 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类 |
| RU2496500C2 (ru) * | 2008-03-05 | 2013-10-27 | Новартис Аг | Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr |
| CL2009001250A1 (es) * | 2008-05-21 | 2010-02-05 | Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras. | |
| MX336723B (es) * | 2008-07-11 | 2016-01-28 | Novartis Ag | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20100267742A1 (en) * | 2009-04-17 | 2010-10-21 | Rush University Medical Center | Combination targeted therapy for lung cancer |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| MX360157B (es) * | 2010-11-08 | 2018-10-24 | Novartis Ag | Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. |
-
2013
- 2013-08-14 US US14/420,792 patent/US20150216870A1/en not_active Abandoned
- 2013-08-14 AU AU2013302702A patent/AU2013302702A1/en not_active Abandoned
- 2013-08-14 RU RU2015108755A patent/RU2705095C2/ru active
- 2013-08-14 JP JP2015527558A patent/JP2015529194A/ja not_active Withdrawn
- 2013-08-14 HK HK15112283.4A patent/HK1211476A1/xx unknown
- 2013-08-14 KR KR1020157003716A patent/KR102245985B1/ko not_active Expired - Fee Related
- 2013-08-14 BR BR112015002528-5A patent/BR112015002528A2/pt not_active Application Discontinuation
- 2013-08-14 EP EP13751058.2A patent/EP2885003B1/en not_active Not-in-force
- 2013-08-14 MX MX2015002005A patent/MX369518B/es active IP Right Grant
- 2013-08-14 IN IN528DEN2015 patent/IN2015DN00528A/en unknown
- 2013-08-14 CN CN201380043882.3A patent/CN105050623B/zh not_active Expired - Fee Related
- 2013-08-14 WO PCT/US2013/054848 patent/WO2014028566A1/en not_active Ceased
- 2013-08-14 ES ES13751058T patent/ES2901712T3/es active Active
- 2013-08-14 KR KR1020217012172A patent/KR20210049187A/ko not_active Ceased
- 2013-08-14 CA CA2879704A patent/CA2879704A1/en not_active Abandoned
-
2016
- 2016-10-06 AU AU2016238903A patent/AU2016238903A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017201774A patent/JP6644042B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-09 AU AU2018201725A patent/AU2018201725A1/en not_active Abandoned
- 2018-10-11 US US16/157,333 patent/US20190083500A1/en not_active Abandoned
-
2019
- 2019-07-30 US US16/526,027 patent/US20190350935A1/en not_active Abandoned
- 2019-09-05 AU AU2019226212A patent/AU2019226212B2/en not_active Ceased
-
2020
- 2020-01-07 JP JP2020000928A patent/JP6970217B2/ja not_active Expired - Fee Related
- 2020-03-17 US US16/820,886 patent/US20200253980A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/644,491 patent/US20220280523A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1211476A1 (en) | 2016-05-27 |
| CN105050623A (zh) | 2015-11-11 |
| CA2879704A1 (en) | 2014-02-20 |
| MX2015002005A (es) | 2015-10-08 |
| KR20150043328A (ko) | 2015-04-22 |
| WO2014028566A1 (en) | 2014-02-20 |
| RU2705095C2 (ru) | 2019-11-05 |
| US20200253980A1 (en) | 2020-08-13 |
| AU2018201725A1 (en) | 2018-04-05 |
| US20190083500A1 (en) | 2019-03-21 |
| MX369518B (es) | 2019-11-11 |
| AU2013302702A1 (en) | 2015-02-19 |
| US20190350935A1 (en) | 2019-11-21 |
| JP2015529194A (ja) | 2015-10-05 |
| JP6970217B2 (ja) | 2021-11-24 |
| JP6644042B2 (ja) | 2020-02-12 |
| AU2019226212B2 (en) | 2020-05-14 |
| RU2015108755A (ru) | 2016-10-10 |
| KR102245985B1 (ko) | 2021-04-30 |
| JP2020079243A (ja) | 2020-05-28 |
| AU2019226212A1 (en) | 2019-09-26 |
| JP2018035188A (ja) | 2018-03-08 |
| EP2885003B1 (en) | 2021-09-29 |
| KR20210049187A (ko) | 2021-05-04 |
| CN105050623B (zh) | 2018-06-12 |
| BR112015002528A2 (pt) | 2018-05-22 |
| US20220280523A1 (en) | 2022-09-08 |
| ES2901712T3 (es) | 2022-03-23 |
| AU2016238903A1 (en) | 2016-10-27 |
| US20150216870A1 (en) | 2015-08-06 |
| EP2885003A1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00528A (esLanguage) | ||
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MY178634A (en) | Topical formulation for a jak inhibitor | |
| IN2015DN00376A (esLanguage) | ||
| MX371119B (es) | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| TW201613577A (en) | Pharmaceutical combinations | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| HK1254635A1 (zh) | C-met抑制剂与pd-1抗体分子的组合及其用途 | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine |